|
Vascular territory | EDHF | Pharmacological agents used |
|
Preclinical studies | | |
Coronary arterioles [8, 9, 29, 73, 118] | H2O2, channels, CYP450 metabolites | Catalase, KCl, charybdotoxin + Apamin, polyethylene glycol catalase, KCl, charybdotoxin, 7-octadecynoic acid |
Internal Mammary artery [6, 62] | 11,12-EET | 17-octadecynoic acid, N-methylsulfonyl-6-(2-propargyloxyphenyl)hexanamide4,15-epoxyeicosa-5(Z)-enoic acid |
Gastroepiploic arteries [4] | channels | KCl |
Mesenteric artery [66, 119] | H2O2, Gap junctions, superoxide dismutase, H2O2 | Catalase, 18 alpha-glycyrrhetinic acid, Tiron (cell-permeable SOD-mimetic), catalase |
Renal artery [10] | K+, channels | KCl, charybdotoxin, and apamin |
Subcutaneous resistance arteries [7] | CYP450 metabolites, channels | Ketoconazole |
Subcutaneous resistance arteries [120] (subcutaneous fat biopsies of healthy pregnant women) | Connexin 43 Gap junctions. | Connexin mimetic peptides |
Visceral fat arterioles | H2O2 | Polyethylene glycol catalase |
Umbilical vein endothelial cells [85, 121] | channels, channels, H2O2 | Apamin and charybdotoxin/triarylmethane-34 |
Thyroid arteries [122] | channels, channels, Na+/K+ ATPase | Iberiotoxin, charybdotoxin, apamin glibenclamide, and barium |
|
Clinical studies | | |
Forearm microvasculature [63] | CYP450 metabolites | KCL, miconazole |
Forearm microvasculature [30, 32, 123] | channels | TEA |
Forearm microvasculature [124] | C-type natriuretic peptide | C-type natriuretic peptide, TEA |
Forearm microvasculature [104] (hypertensive patients) | CYP450 2C9 | Sulfaphenazole |
Forearm conductance vessel [31, 125, 126] | CYP 2C9 metabolites, channels | Sulfaphenazole, TEA, fluconazole |
Thigh skeletal muscle vessels [127] | CYP450 2C9 | Sulfaphenazole |
|